Oseltamivir

C difficile risk
None
Oral Bioavailability
N/A

Spectrum Of Activity

Dosing

3 mg/kg/DOSE PO BID x 5 days

0 - 15 kg15 - 23 23 - 40 kg40+ kg30 mg/DOSE PO BID x 5 days45 mg/DOSE PO BID x 5 days60 mg/DOSE PO BID x 5 days75 mg/DOSE PO BID x 5 days

75 mg/DOSE PO BID x 5 days

Limited data available on dosing in neonates.

Oral: 1 mg/kg/DOSE twice daily; duration not determined.

PNA-days 0 - 13PNA-days 14 - 28 Oral: 3 mg/kg/DOSE once daily for 5 daysOral: 3 mg/kg/DOSE twice daily for 5 days

Renally cleared, requires dosage adjustment with changes in renal function. Consult a pharmacist for renal dosing.

Treatment should ideally begin within 48 hours.

General Information

Treatment and prophylaxis of influenza

GI upset common

Rare - Stevens Johnson Syndrome

Neuropsychiatric side effects reported

Antimicrobial class: Antiviral - neuraminidase inhibitor

Average serum half life:

  • No pediatric data available.

  • Adult: Oseltamivir phosphate: 1-3 hours, oseltamivir carboxylate: 6-10 hours

Route of Elimination: Hepatically metabolixed to >99% of oseltamivir carboxylate (active metabolite) is eliminated by renal excretion via glomerular filtration and tubular secretion